China Universal Asset Management Co., Ltd. Alaunos Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$0.12 - $0.5 $363 - $1,513	3,027 Added 95.97%	6,181 $0
Q3 2023 Oct 30, 2023	BUY	$0.12 - $0.5 $363 - $1,513	3,027 Added 95.97%	6,181 $1,000
Q2 2023 May 21, 2024	SELL	$0.43 - $0.65 $44 - $66	-103 Reduced 3.16%	3,154 $1,000
Q2 2023 Jul 27, 2023	SELL	$0.43 - $0.65 $44 - $66	-103 Reduced 3.16%	3,154 $2,000
Q1 2023 May 21, 2024	BUY	$0.46 - $0.81 $374 - $660	815 Added 33.37%	3,257 $2,000
Q1 2023 Apr 27, 2023	BUY	$0.46 - $0.81 $374 - $660	815 Added 33.37%	3,257 $2,000
Q4 2022 May 21, 2024	BUY	$0.5 - $261.0 $1,221 - $637,362	2,442 New	2,442 $1,000
Q4 2022 Jan 31, 2023	BUY	$0.5 - $261.0 $209 - $109,098	418 Added 20.65%	2,442 $2,000
Q3 2022 Oct 21, 2022	BUY	$1.04 - $322.5 $2,104 - $652,740	2,024 New	2,024 $3,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $398M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account